XML 37 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail) - AstraZeneca Agreements [Member] - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 30, 2013
Dec. 31, 2017
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2015
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2015
U.S./RoW [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Expected upfront, non-contingent and time-based payments $ 374,000              
Development and regulatory approval milestones 550,000              
Commercial sales milestone 325,000              
Shared development costs         $ 233,000      
Additional consideration based on net sales description           Low 20% range    
Milestone payment, revenue recognition     $ 0 $ 0   $ 0 $ 0  
U.S./RoW [Member] | FibroGen, Inc. [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Shared development costs         $ 116,500      
U.S./RoW [Member] | Development Milestones [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Receipt of development milestone payment               $ 15,000
China [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Development and regulatory approval milestones 161,000              
Commercial sales milestone 167,500              
Proceeds from upfront payments 28,200              
Contingent payment $ 20,000              
Estimated joint development service period       2018        
Estimated joint development extended service period       2020        
China [Member] | Scenario, Forecast [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Milestone payment, revenue recognition   $ 15,000